PRMT3 and neoplasm: Moreover, the administration of PRMT3 inhibitor SGC707 effectively disrupted the increased ADMA modification mediated by PRMT3 and attenuated PRMT3‐induced HCC glycolysis and tumour growth (Figure 8).